Clinical trials: Hodgkin Disease Refractory
Peripheral T-cell Lymphomas (PTCL)
Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
This is a single country multi-center, open-label phase Ib/II single-arm study in relapsed or refractory PTCL patients. Patients will be treated with the combination of lenalidomide and gemcitabine until disease progression…
- Trial name
- NCT05105412
- Testing
- Lenalidomide and Gemcitabine (Dose level 11), Lenalidomide and Gemcitabine (Dose level 21), Lenalidomide and Gemcitabine (Dose level 31)
- Where
- 5 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- National Health Research Institutes, Taiwan
Chronic Lymphocytic Leukemia (CLL)
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell…
- Trial name
- NCT01466153
- Testing
- Rituximab, Bendamustine, MEDI-551
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 183 people
- Sponsor
- MedImmune LLC
Lymphoma
Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with relapsed or refractory…
- Trial name
- NCT00516412
- Testing
- everolimus, molecular response by PCR
- Where
- 21 sites in France, Italy and 1 more
- Volunteers
- 35 people
- Sponsor
- Swiss Cancer Institute
Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with…
- Trial name
- NCT04875195
- Testing
- Pembrolizumab
- Where
- 27 sites in United States, Brazil and 9 more
- Volunteers
- 66 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Multi-center, open-label, single-dose, dose-escalating Phase I/II study of GS 9219 in adult patients with relapsed or refractory CLL, NHL or MM. Patients will be enrolled into the study in sequential dose cohorts.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00499239
- Testing
- GS-9219
- Where
- 20 sites in United States, Czechia and 1 more
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
This phase II trial tests the effect of nemtabrutinib in combination with brexucabtagene autoleucel (brexu-cel) in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that…
- Trial name
- NCT07673367
- Testing
- Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Peripheral T Cell Lymphoma
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)
It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of GB226 for the treatment of relapsed and refractory peripheral T cell lymphoma…
- Trial name
- NCT03502629
- Testing
- GB226
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Genor Biopharma Co., Ltd.
T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL)
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
Background: Adult T-cell leukemia (ATL) is a rare blood cancer. Researchers want to see if a combination of two drugs - recombinant human interleukin 15 (rhIL-15) and alemtuzumab - is a better treatment for ATL.
- Conditions
- T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T Cell Lymphoma (CTCL)
- Trial name
- NCT02689453
- Testing
- IL-15 plus, alemtuzumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).
- Conditions
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Mantle Zone Lymphoma Refractory/Recurrent
- Trial name
- NCT02981745
- Testing
- CT-1530
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Centaurus Biopharma Co., Ltd.
Diffuse Large B-cell Lymphoma
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
A multi-center, open-label, phase Ib study to evaluate the safety and tolerability of the administration of tisagenlecleucel in combination with ibrutinib in patients with r/r DLBCL who have received two or more lines of systemic…
- Trial name
- NCT03876028
- Testing
- Tisagenlecleucel, Ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R…
- Trial name
- LuminICE-203 (NCT05883449)
- Testing
- AFM13, AB-101, Cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- Affimed GmbH
Hodgkin's Lymphoma
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
This clinical trial is for patients with Hodgkin Lymphoma that has not responded to standard treatment. The purpose of this study is to determine what effects, good or bad, Temsirolimus has on Hodgkin Lymphoma.
- Trial name
- NCT00838955
- Testing
- Temsirolimus
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Loyola University
Non-Hodgkin's Lymphoma
Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed…
- Trial name
- NCT03074825
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Chipscreen Biosciences, Ltd.
T-cell Lymphoma, Aggressive B-cell Lymphoma
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
The purpose of this study is to evaluate how well the study drug works and safety of oral decitabine in patients with refractory or relapsed lymphoid malignancies.
- Conditions
- T-cell Lymphoma, Aggressive B-cell Lymphoma, Non-Hodgkin's Lymphomas, Indolent B-cell Lymphoma
- Trial name
- NCT02846935
- Testing
- Decitabine, Tetrahydrouridine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Yogen Saunthararajah
B-cell Non Hodgkin Lymphoma, Relapse
Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study
The goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the Compassionate Use Program, in relapsed/refractory B-NHL patients.
- Conditions
- B-cell Non Hodgkin Lymphoma, Relapse, Refractory Lymphoma
- Trial name
- NCT05927558
- Where
- Italy
- Volunteers
- 59 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL)
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia.
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
- Trial name
- NCT07205315
- Testing
- GT801 Injection
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Grit Biotechnology
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood.
- Conditions
- Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy
- Trial name
- IMAGINE (NCT05138458)
- Testing
- MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Myeloid Therapeutics
Lymphoma, B-Cell, CAR-T
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
- Trial name
- NCT06210243
- Testing
- C752
- Where
- China
- Volunteers
- 2 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
This study will examine the effects of an experimental drug called UCN-01 (7-hydroxystaurosporine) on T-cell lymphomas. UCN-01 inhibits the growth of several different tumor cells, and, in laboratory studies, it has worked…
- Trial name
- NCT00082017
- Testing
- UCN-01 (7-hydroxystaurosporine)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.